9月21日，在由中国睡眠研究会主办的2025年中国睡眠医学发展论坛上，多项失眠治疗相关的新数据、 新方法、新举措发布，与会专家呼吁各界关注和重视睡眠问题。在失眠治疗方面，随着今年以来两款创 新失眠药物相继在国内获批上市，临床专家指出，失眠治疗已进入双食欲素受体拮抗剂（DORA）时 代。 逐渐扩增的失眠人群 根据中国睡眠研究会《2025年中国睡眠健康调查报告》，中国18岁及以上人群睡眠困扰率为48.5%，主 要症状表现为入睡困难、夜间易醒、早醒等。头豹研究院报告数据显示，在国内，2016年至2020年失眠 症成人患病人数从2.5亿增至2.7亿，预计2030年将增至3.3亿。 中国科学院院士陆林教授指出，失眠和高血压、糖尿病、冠心病、癌症都密切相关，长期失眠也会增加 痴呆风险。65岁以上老年人应睡够5-6小时，成年人则要睡够7-8小时。 目前国内失眠领域的创新药赛道尚未形成稳定市场格局，但已有多家本土企业布局。先声药业早在2022 年与Idorsia达成了协议，获得了达利雷生在大中华地区的开发及商业化独家权利，目前已实现商业化上 市。扬子江药业、翰森制药、广东东阳光药业、布瑞迅药业等均有布局DORA药物，其中，扬 ...

"睡不着"是当代成年人的烦恼之一。 头豹研究院报告数据显示，在国内，2016年至2020年失眠症成人患病人数从2.5亿增至2.7亿，预计2024 年达3亿，2030年将增至3.3亿。对应地，中国睡眠经济市场规模日益增长，2021年，中国失眠药物市场 规模为122.8亿元，预计2025年达151.2亿元，至2030年将达到211.9亿元。 公开资料显示，由于国内创新药企主要聚焦肿瘤、自身免疫等市场空间巨大的热门赛道，对失眠类创新 药研发较少，目前已进入临床阶段的DORA失眠创新药包括扬子江药业的YZJ-1139、东阳光（600673） 药的HEC-83518。 在新的药物获批前，莱博雷生和达利雷生仍是主要的新型失眠药物。吉林大学第一医院王赞教授告诉记 者，对于从未使用过相关药物的患者来说，这两种药物均能有效改善睡眠总时长、缩短睡眠潜伏期，并 减少睡眠中的觉醒时间。如果患者对日间功能的要求较高，欧洲相关临床指南建议优先选择半衰期更短 的达利雷生。 造成这种现象主要有两个原因：一方面，传统抗失眠药物主要为苯二氮类和非苯二氮类镇静催眠药，其 虽能缩短入睡时间，却存在"日间嗜睡、认知损伤、药物依赖"等副作用。另一方面， ...

9月18日，由中国睡眠研究会牵头组织编写的《莱博雷生临床应用中国专家共识》正式发布。莱博雷生 作为新型催眠药，是中国首个获批上市的食欲素双受体拮抗剂(DORA)，通过靶向调节睡眠-觉醒系统， 为失眠治疗提供了全新路径。 南方医科大学南方医院药剂科李亦蕾教授指出，莱博雷生的创新机制，使失眠治疗从传统药物的"广泛 镇静"转向"精准调控"，助力机体回归自然睡眠节律，不仅更符合生理性睡眠过程，其低依赖风险的特 性更为需要长期管理的失眠患者提供了安全可靠的新选择。 中国睡眠研究会理事长黄志力表示，失眠的规范诊疗是当前睡眠医学发展的重点。共识汇聚了国内专家 的临床经验与科学证据，不仅为莱博雷生这一新机制药物的合理使用提供指导，也将进一步推动我国失 眠诊疗向标准化、个体化和高质量方向发展。(经济日报记者郭静原) 失眠既可以是一种症状，也可以是独立的疾病。普通人群中，失眠症状的发生率高达30%~48%。失眠 显著干扰患者的生活质量和工作表现，且与躯体疾病、精神障碍等疾病相关。 为响应临床对规范化用药指导的迫切需求，中国睡眠研究会联合广东省医师协会睡眠医学专业委员会、 广东省医院协会医院药事管理专业委员会，组织多学科专家基于国 ...

Core Viewpoint - The National Healthcare Security Administration (NHSA) has announced the preliminary review results for the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance drug catalog, along with the commercial insurance innovative drug catalog, indicating a significant increase in the number of drugs under review and the introduction of a new commercial insurance category for innovative drugs [1][3]. Group 1: Drug Catalog Submission and Review - A total of 718 submissions were received for the basic medical insurance catalog, involving 633 drug generic names, with 534 passing the preliminary review [3]. - For the commercial insurance innovative drug catalog, 141 submissions were received, involving 141 drug generic names, with 121 passing the preliminary review, including 79 drugs that may be negotiated under both insurance schemes [3][4]. Group 2: Impact on the Pharmaceutical Industry - The introduction of the commercial insurance innovative drug catalog is expected to create new pathways for multi-channel payment for innovative drugs and promote collaboration between commercial insurance and basic medical insurance [3]. - The review process for drugs that have passed the preliminary review does not guarantee inclusion in the final catalog, as they must undergo strict evaluation and successful negotiations [4]. Group 3: Notable Drugs and Categories - The commercial insurance catalog includes 12 monoclonal antibodies, 3 CAR-T therapies, and other innovative drugs, with notable products like CAR-T therapies and PD-1 inhibitors included [5][6]. - There are 42 drugs that only passed the preliminary review for the commercial insurance catalog, primarily from major pharmaceutical companies [6]. Group 4: Future Negotiation Timeline - The NHSA plans to conduct negotiations for the 2025 insurance catalog between September and October, with results expected to be announced between October and November [7].

Core Insights - The article highlights the widespread issue of insomnia in China, affecting over 500 million people, with 48.5% of individuals aged 18 and above experiencing sleep disorders [1][20]. - Insomnia is often linked to psychological issues such as anxiety and depression, creating a cycle where sleep problems exacerbate emotional distress [6][15]. - New medications, such as "Lai Bolai Sheng," have been approved in China, offering a non-sedative option for treating insomnia, which could improve accessibility and reduce dependency on traditional sleeping pills [18][19]. Group 1: Insomnia Statistics and Characteristics - A significant portion of the population suffers from insomnia, with a notable prevalence among various age groups and a strong psychological correlation [1][20]. - The typical characteristics of insomnia sufferers include low treatment rates and a strong connection to social pressures and lifestyle choices [1]. Group 2: Psychological Impact and Coping Mechanisms - Many individuals with insomnia experience deep-seated emotional pain and anxiety, often stemming from childhood experiences or societal expectations [2][8]. - Various coping strategies are employed by insomnia sufferers, including storytelling, counting, and other unconventional methods, though these often fail to address the underlying issues [7][12]. Group 3: Medication and Treatment Options - The article discusses the challenges associated with traditional sleeping medications, including side effects and dependency issues [15][16]. - The introduction of "Lai Bolai Sheng" represents a significant advancement in insomnia treatment, as it is not classified as a controlled substance and can be purchased online, enhancing accessibility for patients [18][19]. Group 4: Personal Recovery Journeys - Individuals are finding ways to cope with and overcome their insomnia through various means, including therapy, lifestyle changes, and medication adjustments [20]. - The narrative emphasizes the importance of addressing both psychological and physical aspects of insomnia for effective recovery [20].

Core Insights - Eisai (China) Pharmaceutical Co., Ltd. has announced that its innovative drug, Lemborexant, has arrived in China and completed the drug inspection process, now being distributed to major hospitals and designated pharmacies nationwide, providing a new treatment option for insomnia patients [1][2] - Lemborexant can also be prescribed through the JD Health online platform, addressing the medication needs of insomnia sufferers [1] - The drug works by competitively binding to two orexin receptor subtypes (OX1R and OX2R), precisely regulating the orexin system to induce sleep without suppressing REM sleep, thus improving overall sleep structure [1][2] Product Approval and Market Position - Lemborexant was approved for sale in the United States in 2019 and has since received approval in over 20 countries and regions, including Japan, Canada, Australia, Hong Kong, and Macau [2] - In the U.S., it is indicated for adults with difficulties in falling asleep or maintaining sleep, while in Japan, it is a recommended treatment for insomnia as per the Japanese Consensus on Insomnia Disorder Treatment [2] - The drug received approval from the National Medical Products Administration (NMPA) in China in May 2025 for treating adult insomnia characterized by difficulty in falling asleep and/or maintaining sleep, and is included in the "Guidelines for the Diagnosis and Treatment of Adult Insomnia in China" [2] Strategic Focus - Eisai China positions the neuroscience field, including insomnia, as a key therapeutic area, aiming to provide innovative treatment options and management tools for insomnia patients [2] - The launch of Lemborexant is expected to reshape natural sleep rhythms and redefine sleep health management standards, contributing to the "Healthy China 2030" chronic disease prevention goals [2]

Core Viewpoint - The launch of the innovative insomnia drug, Lemborexant (brand name: Davaiq), on Meituan marks a significant development in the treatment options available for insomnia patients in China, particularly as it is the first approved dual orexin receptor antagonist that is not classified as a controlled substance [1][2]. Group 1: Product Overview - Lemborexant is designed to treat adult patients with insomnia characterized by difficulties in falling asleep and/or maintaining sleep, and it has not been found to have addictive properties since its market introduction [1]. - The drug was approved by the National Medical Products Administration in May 2023 and is reported to shorten sleep onset time, reduce nighttime awakenings, and extend total sleep time, positively affecting sleep structure [1][2]. Group 2: Market Context - According to the "2025 China Sleep Health Survey Report," approximately 485 million people in China suffer from sleep-related issues, highlighting a significant market opportunity for insomnia treatments [1]. - Prior to Lemborexant, insomnia medications were primarily classified as controlled substances, which limited treatment options for patients [1]. Group 3: Clinical and Regulatory Insights - Clinical trials indicate that Lemborexant has minimal impact on memory and cognitive function, allowing patients to resume daily activities, including driving, without significant impairment [2]. - The drug has been included in the "Chinese Adult Insomnia Diagnosis and Treatment Guidelines (2023 Edition)" as an IA-level recommendation, further validating its clinical efficacy [2]. Group 4: Distribution and Accessibility - Meituan has facilitated the purchase of Lemborexant through its platform, allowing patients to order the medication with a prescription and receive it via home delivery within 48 hours, with compensation offered for any delays [2]. - The trend of online platforms becoming significant channels for new drug purchases is growing, with Meituan having launched seven new drugs since last year, covering various therapeutic areas including GLP-1, myopia, gout, and insomnia [2].

Group 1 - Meituan's pharmaceutical health division has launched a new insomnia treatment drug, Lemborexant, which is the first approved dual orexin receptor antagonist, providing a new treatment option for adult insomnia patients [1] - The drug is not classified as a controlled substance and has not shown addictive properties since its launch [1] - According to the "2025 China Sleep Health Survey Report," approximately 485 million people in China suffer from sleep issues, highlighting the significant market potential for insomnia treatments [1] Group 2 - Meituan has actively introduced innovative drug products, having launched seven new drugs since last year, including Lemborexant, covering various medical fields such as GLP-1, myopia, gout, and insomnia [2] - The company aims to enhance the accessibility of innovative drugs through its e-commerce platform, allowing patients to order medications conveniently [2]